Clinical Trial Update: Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating whether pexelizumab affects all-cause mortality and myocardial infarction in patients undergoing coronary artery bypass graft su…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Pexelizumab (pexelizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Cardio-pulmonary Bypass, Coronary Artery Bypass Graft | Phase 3 | Status: COMPLETED